AMGNAmgen Inc

CSNasdaq (XNAS)·USD

Identity

Security key: 11660
Ticker: AMGN
Type: CS — Common Stock
Exchange: Nasdaq(XNAS)
Venue group: NASDAQ
Operating MIC: XNAS
Market: stocks
Locale: us
Currency: USD
Listed: 1983-06-17
Round lot: 40
Active: Yes
Last seen in a load: 2026-08-14 20:49
Vendor updated: 2026-08-13 06:09
Ticker root / suffix: AMGN

Detail

Enriched 2026-08-14 20:47

Market cap: $225,153,380,000
Shares outstanding (class): 540,632,005
Shares outstanding (weighted): 541,000,000
SIC: 2836 BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Employees: 31,500
Location: THOUSAND OAKS, CA
Homepage: https://www.amgen.com
Description: Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis, which has been further strengthened with the launch of new drugs in blood cancers (Blincyto) and solid tumors (Imdelltra). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.

Market cap and share counts drift.

Funds holding this security

547 funds · 586 positions · $41.22B reported value, as of 2026-03-31

All holders →

Fund	Ticker	Position value	% of fund	Balance	Match
VANGUARD TOTAL STOCK MARKET INDEX FUND VANGUARD INDEX FUNDS	VTI	$6.02B	0.30%	17,121,005 NS	FIGI
VANGUARD 500 INDEX FUND VANGUARD INDEX FUNDS	VOO	$4.81B	0.34%	13,684,554 NS	FIGI
Invesco QQQ Trust, Series 1 Invesco QQQ Trust, Series 1	QQQ	$4.00B	1.07%	11,356,021 NS	FIGI
American Balanced Fund American Balanced Fund	—	$2.44B	0.93%	6,940,187 NS	FIGI
iShares Core S&P 500 ETF iShares Trust	IVV	$2.44B	0.34%	6,925,525 NS	FIGI
N/A —	—	$2.21B	0.34%	6,270,087 NS	FIGI
VANGUARD PRIMECAP FUND VANGUARD CHESTER FUNDS	—	$1.94B	2.68%	5,523,646 NS	FIGI
VANGUARD VALUE INDEX FUND VANGUARD INDEX FUNDS	VTV	$1.75B	0.78%	4,986,178 NS	FIGI
State Street(R) Health Care Select Sector SPDR(… SELECT SECTOR SPDR TRUST	XLV	$1.38B	3.57%	3,918,600 NS	FIGI
American Funds Fundamental Investors American Funds Fundamental Investors	—	$1.33B	0.87%	3,785,891 NS	FIGI
VANGUARD INSTITUTIONAL INDEX FUND VANGUARD INSTITUTIONAL INDEX FUNDS	—	$1.07B	0.34%	3,036,218 NS	FIGI
JPMorgan Large Cap Growth Fund JPMorgan Trust II	—	$918.25M	0.85%	2,609,777 NS	FIGI
iShares Biotechnology ETF iShares Trust	IBB	$609.81M	7.51%	1,733,148 NS	FIGI
VANGUARD CAPITAL OPPORTUNITY FUND VANGUARD HORIZON FUNDS	—	$602.39M	2.45%	1,712,059 NS	FIGI
iShares Russell 1000 Growth ETF iShares Trust	IWF	$562.91M	0.50%	1,599,847 NS	FIGI

How positions resolve to the securities master. FIGI_COMPOSITE is exact identifier equality — both sides got the FIGI from Bloomberg. TICKER is a narrow fallback used only where the master row carries no FIGI at all (2,389 rows do not, disproportionately Irish-domiciled US listings like LIN and ACN). Roughly 22% of all positions resolve to the master.

Funds holding this security

Identifiers

master.security_identifier

TICKERAMGN
FIGI_COMPOSITEBBG000BBS2Y0
FIGI_SHARE_CLASSBBG001S5NNL6
CIK0000318154
ISINUS0311621009
Resolved through OpenFIGI from a holdings ISIN, not supplied by the securities vendor.

Identifiers

Classification

classification.v_security_classification

Asset class: Equity
Sector: Health Care
Industry: Biotechnology
Source: LLMunreviewed
Self-reported confidence: 0.95
Model: deepseek
Rationale: Amgen is a biotechnology company focused on biological products, fitting the healthcare sector and biotechnology industry.

Classifications are unreviewed model output. All 5,771 assignments carry source = LLM and is_reviewed = false. Confidence is the model’s own estimate and is not calibrated — it clustered at 0.90–0.98 across the whole first pass, including rows that later proved wrong. Use it to order a review queue, not as a probability. Two share classes of one issuer can disagree.

Classification

Fund data

Not linked to a fund series.

Either this is not a fund, or it is one the SEC share-class snapshot cannot reach — commodity trusts and notes have no series ID at all.